Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.

Abstract excerpt

Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive activation of the KRAS protein, which acts as a molecular switch to persistently stimulate downstream signaling pathways, including cell proliferation and survival,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Combined Modality Therapy
• Share to Disease Management
• Share to Disease Susceptibility